Drugs / NAC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02259595 | Oct 2014 → Jan 2015 | noise induced hearing loss, sensorineural hearing loss disorder | Otologic Pharmaceutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259595 ↗ |
| Route | Oral | “1,200mg NAC administered via oral capsule in single dose” NCT02259595 ↗ |